Consort Medical PLC

Consort Medical PLC is a UK-based company specializing in innovative drug delivery systems and devices, focusing on enhancing patient outcomes in the healthcare sector. Founded in 1946 and headquartered in Hemel Hempstead, UK, Consort Medical PLC develops and manufactures drug delivery systems. The company has maintained a consistent focus on the healthcare sector, without significant pivots or changes in its core business strategy. Consort Medical is not noted as a subsidiary of another firm and does not have publicly available information regarding previous founders or other companies.

The company has participated in several funding rounds, although specific details are not disclosed. Consort Medical specializes in the development and manufacturing of innovative drug delivery systems and devices, primarily focusing on the healthcare sector. The company’s core product offerings encompass inhalation devices, medical device manufacturing services, and other specialized delivery systems designed to facilitate the efficient delivery of pharmaceuticals to patients. These products aim to address critical healthcare needs, particularly in the management of respiratory conditions and chronic diseases, by enhancing patient adherence and optimizing therapeutic outcomes.

Consort Medical serves a diverse clientele that includes major pharmaceutical companies and healthcare providers across North America, Europe, and Asia, reflecting a broad geographic market presence. The company's product solutions are designed to meet rigorous regulatory standards, ensuring functionality and safety for end users, which include patients who rely on these devices for their daily medication delivery. Consort Medical generates revenue primarily through B2B transactions, partnering with pharmaceutical companies and healthcare organizations to provide customized drug delivery solutions and manufacturing services. Revenue streams typically include contractual agreements for product development and manufacturing, with a focus on long-term partnerships that enhance their clients’ product offerings.

The company reported a revenue of USD 0 mn for the year 2021 and an EBITDA of USD 262,749. 6 for the same year. The company is actively designing new products focused on enhancing drug delivery systems, though specific release dates are not disclosed. Consort Medical is exploring opportunities to expand into emerging markets across Asia and South America by 2023.

Recent funding will be utilized to support product development initiatives and expand their manufacturing capabilities in these targeted regions.